GO
Loading...

Pharmaceuticals

More

  • The $2 Difference Thursday, 25 Jan 2007 | 3:56 PM ET

    So, an overwhelming majority of Icos shareholders voted for the Lilly buyout offer. Lilly originally offered $32 per share, but under pressure from proxy advisory firms and big investors, the company raised its bid to $34 per share. And: the United Kingdom's government health care program announced today that it is not going to spring for Erbitux or Avastin from Genentech and Roche.

  • Competition Hurts Two Drug Companies Thursday, 25 Jan 2007 | 1:12 PM ET

    Generics hurt sales of Bristol-Myers Squibb's top-selling and most profitable drug Plavix, and Bristol-ImClone cancer drug Erbitux. Also: This afternoon, ICOS shareholders vote on the Eli Lilly buyout offer -- see the results ASAP on CNBC.com.

  • Cardinal to Sell Drug Unit for $3.3 Billion; Profit Up Thursday, 25 Jan 2007 | 10:26 AM ET

    Cardinal, one of the nation's top three drug distributors, made good on newly appointed Chief Executive R. Kerry Clark's promise in November to sell the underperforming unit and focus on reshaping the company.

  • An Energy Run At Davos--And Remember Quattrone? Thursday, 25 Jan 2007 | 9:16 AM ET

    Wall Street is undecided so far on where it will start the day though early earnings news and housing data could help set the tone. For now, eBay's strong profits and big stock move is a bright spot lifting the Nasdaq, which bounced higher on a tech rebound yesterday. The Dow, fresh off its 26th high since October, is flattish.

  • Novartis Confident on 2007 Drug Approvals Thursday, 25 Jan 2007 | 6:02 AM ET

    Novartis CEO Daniel Vasella talked to "Worldwide Exchange" about the prospects for an eye medication just approved by the EU and also weighs on global intellectual property rights.

  • Layoffs a Bitter Pill for Employees and Investors Tuesday, 23 Jan 2007 | 1:31 PM ET

    As I write this Pfizer shares are down about 2.5% in intra-day trading on top of the 1% loss yesterday.  Usually investors cheer when a company announces substantial cost cuts--10,000 jobs, as many as eight facility closures or sales, $1.5 billion-$2 billion in savings by the end of '08. Yesterday you could argue the move was simple selling on the news as the layoffs and cost cuts had been leaked a week ahead of the meeting.  But today ...

  • Pfizer to Slash 10,000 Jobs in Cost-Cutting Move Monday, 22 Jan 2007 | 2:06 PM ET

    Pfizer also provided per-share earnings guidance for 2007 in the range of $2.18 to $2.25, which would represent growth of between 6% and 9%. A Thomson Financial consensus estimate puts the company's earnings at $2.19 for the year.

  • The drugmaker earned $9.45 billion in the fourth quarter, or $1.32 a share, compared with $2.73 billion, or 37 cents a share, a year earlier.

  • AstraZeneca to Increase Work on Research Monday, 22 Jan 2007 | 10:59 AM ET

    Pharmaceutical company AstraZeneca unveiled plans to boost its work in the infectious disease and cancer research with a U.S.$100 million (euro77 million) funding injection into its research and development center near Boston.

  • Vioxx Plaintiff Drops Suit, Merck Says Monday, 22 Jan 2007 | 10:32 AM ET

    Merck said a plaintiff who alleged the drugmaker's Vioxx painkiller caused her husband's heart attack and death dropped her lawsuit five weeks before the trial was to start.

  • Potent Growth in Impotence Drug Market Friday, 19 Jan 2007 | 12:51 PM ET

    The Eli Lilly-Icos joint venture reported that worldwide sales of their erectile dysfunction drug came to $971 million last year -- and is now on the cusp of becoming a billion-dollar blockbuster drug in 2007.  We will find out how Viagra is doing when Pfizer reports earnings before the bell on Monday morning, but sales growth is expected to have picked up.  These results represent a significant turnaround in a drug segment that some thought had already had its day.

  • Deadlock Jury Results in Mistrial for Vioxx Lawsuits Friday, 19 Jan 2007 | 11:59 AM ET

    A hung jury forced a mistrial in lawsuits by two men who blamed their heart attacks on Vioxx, the once-popular painkiller made by pharmaceutical company Merck.

  • Pfizer Expected to Cut Staff as Part of Overhaul Friday, 19 Jan 2007 | 11:55 AM ET

    Pfizer may announce $2 billion in cost cuts including plant closings and slashing up to 10% of the work force when new chairman and CEO Jeffrey Kindler announces his plan next week for a strategic overhaul of the world's largest drugmaker, analysts say.

  • Novartis Fourth-Quarter Profit Climbs 23% Thursday, 18 Jan 2007 | 10:04 AM ET
    Novartis

    Swiss pharmaceutical giant Novartis said Thursday fourth-quarter net income rose 23% thanks to double-digit percentage sales growth in top-selling blood pressure and blood cancer drugs.

  • German drugmaker Merck said Thursday its fourth-quarter profit rose 18% after the company boosted sales of its Erbitux cancer treatment.

  • Jan. 22: Two, Too Much to Cover Wednesday, 17 Jan 2007 | 1:54 PM ET

    As we get into the thick of earnings season, next Monday is shaping up to be a big news day for big pharma. Before the bell Pfizer will put out its press release with its 2006 and fourth-quarter numbers.  Then, at 1 p.m. ET the company is holding an analyst meeting in midtown Manhattan where "The Wall Street Journal" reports Pfizer will announce more job cuts and other changes in the way it does business  ...  Meantime, in lower Manhattan the patent trial over Bristol-Myers Squibb's blockbuster bloodthinner Plavix gets underway on Monday morning ... And, finally, opening arguments are set for Monday morning in the two-in-one Vioxx trial in Atlantic City ...

  • Pfizer Prepares Major Overhaul, Buys Stake in Genizon Tuesday, 16 Jan 2007 | 11:21 AM ET

    Pfizer's new chief executive is preparing a plan to overhaul the drug maker that could include cutting several thousand jobs and changing the way it develops, makes and markets medicines, The Wall Street Journal reported on Tuesday.

  • Drugmaker Schwarz Pharma Gets Nod for Parkinson's Drug Tuesday, 16 Jan 2007 | 8:35 AM ET

    Drug maker Schwarz Pharma said Tuesday that its Neupro treatment for Parkinson's disease has received approval in Europe to treat the illness in its advanced stages.

  • Day Ahead: Earnings, OPEC and BP Safety Report Tuesday, 16 Jan 2007 | 8:22 AM ET

    Lots of corporate headlines are already getting attention ahead of the open. Stocks in the U.S. are lining up to open higher at this point, and earnings will be the big focus. After making gains yesterday, European stocks are mixed with a flattish performance, and Japanese stocks were little changed to the downside.

  • CNBC's Domm: A Very Busy Week Ahead Sunday, 14 Jan 2007 | 11:33 AM ET

    Financials and techs, two groups that pulled in the money last week, will be out in front of the news this week when earnings season is in full swing. Markets will also be watching key economic data, a parade of Fed speakers and whatever side show goes on when oil markets reopen, after last week's near six percent slide in crude.

Most Popular Video

Wednesday, 16 Apr 2014 | 9:37 AM ET

CNBC's Bob Pisani looks at what's likely to move in early morning trading, including the public debut of Moelis & Company, and a look at bank earnings and market leaders.

Wednesday, 16 Apr 2014 | 7:50 AM ET

John Calipari, University of Kentucky basketball coach, discusses building "servant leadership" in his team, and the big business of college basketball.

Wednesday, 16 Apr 2014 | 9:04 AM ET

The "Squawk on the Street" news team break down Bank of America's Q1 earnings loss thanks largely to legal expenses related to the financial crisis.